Database for
Therapeutic Antibodies
Therapeutic Antibodies
| Entry ID | 2004 |
| INN | Figitumumab |
| Status | Terminated |
| Drug code(s) | CP-751,871 |
| Brand name | None |
| mAb sequence source | mAb human |
| General Molecular Category | Naked monospecific |
| Format, general category | Full length Ab |
| Format details | None |
| Isotype (Fc) | IgG2 |
| Light chain isotype | kappa |
| Linker | None |
| Ave. DAR | None |
| Conjugated/fused moiety | None |
| Discovery method/technology | Transgenic mouse-derived (Xenomouse) |
| Target(s) | IGF-1R |
| Indications of clinical studies | Non-small cell lung cancer, multiple myeloma, breast cancer, prostate cancer, small cell lung cancer |
| Primary therapeutic area | Cancer |
| Most advanced stage of development (global) | Terminated at Phase 3 |
| Status | Inactive |
| Start of clinical phase (IND filing or first Phase 1) | December 15, 2003 |
| Start of Phase 2 | January 19, 2006 |
| Start of Phase 3 | March 15, 2008 |
| Date BLA/NDA submitted to FDA | |
| Year of first approval (global) | None |
| Date of first US approval | |
| INN, US product name | None |
| US or EU approved indications | None |
| Company | Pfizer |
| Licensee/Partner | Abgenix |
| Comments about company or candidate | Phase 3 study in NSCLS discontinued following an independent DSMC recommended the trial be stopped after concluding that the addition of figitumumab was unlikely to demonstrate a significant improvement on the primary endpoint. Phase 2 study in breast cancer was closed to enrollment as of 13 May 2011 due to business reasons. Premature closure was not prompted by any safety or efficacy concerns |
| Full address of company | 66 Hudson Boulevard East, New York, NY 10001-2192 USA North America United States of America https://www.pfizer.com/contact |
None
| Anticipated events | None |
| Factor(s) contributing to discontinuation | Business reasons |